默沙东(Merck)旗下在研口服PCSK9抑制剂Enlicitide Decanoate的最新临床数据显示,在现有他汀类药物治疗基础上,该药物在八周内实现的低密度脂蛋白胆固醇(LDL-C)降幅显著优于现行指南推荐的口服非他汀疗法。这一突破性进展为高胆固醇血症患者提供了更具潜力的治疗选择。
默沙东(Merck)旗下在研口服PCSK9抑制剂Enlicitide Decanoate的最新临床数据显示,在现有他汀类药物治疗基础上,该药物在八周内实现的低密度脂蛋白胆固醇(LDL-C)降幅显著优于现行指南推荐的口服非他汀疗法。这一突破性进展为高胆固醇血症患者提供了更具潜力的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.